Comparison of the effectiveness and safety of intravenous and topical regimens of tranexamic acid in complex tibial plateau fracture: a retrospective study

Zhimeng Wang  
Xi’an Hong Hui Hospital

Yao Lu  
Xi’an Hong Hui Hospital

Qian Wang  
Xi’an Hong Hui Hospital

Leilei Song  
Qinghai University

Teng Ma  
Xi’an Hong Hui Hospital

Cheng Ren  
Xi’an Hong Hui Hospital

Zhong Li  
Xi’an Hong Hui Hospital

Jiarui Yang  
Xi’an Hong Hui Hospital

Kun Zhang  (hhzhangkun@163.com)  
The Second Affiliated Hospital of Xi’an Medical College

Research article

Keywords: Tranexamic acid, hyperfibrinolysis, tibial plateau fracture

Posted Date: November 3rd, 2020

DOI: https://doi.org/10.21203/rs.3.rs-42574/v4

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Version of Record: A version of this preprint was published on November 12th, 2020. See the published version at https://doi.org/10.1186/s12891-020-03772-7.
Abstract

Background Previous studies have demonstrated the effectiveness and safety of tranexamic acid (TXA) in orthopedic surgery. However, no study has investigated TXA in complex tibial plateau fracture surgery. Therefore, the purpose of this study was to confirm the safety and effectiveness of i.v. (intravenous) TXA and topical TXA.

Material and methods This was a retrospective analysis of prospectively collected data. The control group received an equal amount of placebo (physiological saline solution); the i.v. group received 1.0 g TXA by intravenous injection before the tourniquet was inflated and before the surgical incision was closed, and the topical group received 3.0 g TXA in 75 mL of physiological saline solution 5 minutes prior to the final tourniquet release. Perioperative blood loss, vascular events, wound complications, and adverse reactions were compared among the three groups. The pain, knee function, and quality of life (QoL) assessments were based on their corresponding scoring systems.

Results Baseline data were comparable for all groups. The i.v. group showed the best results for total blood loss (TBL) and hidden blood loss (HBL) (424.5 ± 49.4 mL and 219.3 ± 33.4 mL, respectively, all P values < 0.001). Patients in the i.v. group had lesser real Hb decrease than those in the control group (0.9 vs 1.5, P<0.001) and topical group (0.9 vs 1.2, P = 0.026). The blood coagulation level as measured using fibrinolysis (D-dimer) was lower in the i.v. group than in the control and topical groups on POD1 and POD3; however, this difference was not significant; the fibrin-degradation products also showed a similar trend. Patients in the topical group experienced less pain than those in the control group on POD2, POD4, and PO6W. The VAS pain score was 3.6 vs. 4.4 (POD2, P<0.05), 2.8 vs 3.3 (POD4, P<0.05), and 2.1 vs. 2.6 (PO6W, P<0.001) in the topical group vs control group, respectively. No significant differences were identified in vascular events, wound complications, adverse reactions, knee function, and QoL among the three groups.

Conclusion To our knowledge, this is the first study that showed both i.v. TXA and topical TXA are safe and effective for complex tibial plateau fractures. The i.v. regimen effectively reduced blood loss during the perioperative period, whereas patients under the topical regimen had less vascular events, wound complications, and a lower incidence of adverse reactions compared to those in the i.v. group.

Background

Tibial plateau fractures are mostly caused by high-energy direct impact; however, the incidence of osteoporotic fracture of the tibial plateau increases with age\textsuperscript{1,2}. For this type of fracture, surgical treatment can improve the quality of life (QoL) of patients as well as their knee function\textsuperscript{3}. Most simple types of tibial plateau fractures (Schatzker I–III) are not difficult to treat. Owing to the local anatomic characteristics of the posterior and lateral sides of the tibial plateau, exposure and fixation of complex tibial plateau fractures (Schatzker V and VI) represent major challenges\textsuperscript{4}. Schatzker type II and III tibial plateau fractures are usually caused by severe crushing and collapse of the medial and lateral condyles,
usually owing to high-energy trauma. The use of posteromedial and anterolateral incisions combined with bone grafting and double plate fixation can maintain the absolute stability of the tibial plateau while also satisfying the biological effects of the bone and surrounding soft tissues. Since there is an abundance of blood vessels around the knee joint, an increase in the incision exposure range and the use of tourniquets can lead to profuse blood loss and fibrinolytic response during the perioperative period.

Antifibrinolytic therapy, an important aspect of blood management that is considered to be closely related to the concept of enhanced recovery after surgery (ERAS), has emerged as a particular research focus.

Tranexamic acid (TXA) is a traditional antifibrinolytic drug that binds to lysine residues and forms a reversible complex with plasminogen and plasmin. It is an effective agent against plasmin, tissue plasminogen activators, and plasminogen. Several studies have reported that TXA can effectively reduce the rate of perioperative blood transfusion, blood loss, and drainage volume without increasing the risk of deep vein thrombosis (DVT) formation in trauma orthopedics. In addition, it has been shown to be cost-effective.

Currently, TXA is administered as intravenous, intramuscular, topical, and oral regimens. Since the safety of intramuscular and oral regimens has not been supported by a large number of clinical trials, these routes of administration were excluded from our study. Some scholars have suggested that when TXA is used topically in the joint cavity, the drainage must not be placed after surgery to avoid loss of drug efficacy. Therefore, to reduce bias in test results, a temporary clamping scheme for the drainage tube after the operation was used in this study.

Given the encouraging results for TXA, we designed this study to evaluate the efficacy and safety of the intravenous and topical use of TXA in Schatzker V and VI tibial plateau fractures. We hypothesized that, compared to the control group, both intravenous TXA and topical TXA regimens can reduce blood loss and facilitate postoperative recovery without increasing thromboembolic complications.

Materials And Methods

The present study is a part of a randomized controlled trial (RCT), which is registered in the Chinese Clinical Trial Registry (ChiCTR-TRC-1800017754); thus, the reported study is a retrospective analysis of prospectively collected data. Approval was obtained from the Clinical Trials and Biomedical Ethics Committee of Hong Hui Hospital (Approval Number: 2018002), and written informed consent was obtained from all participants.

Patients

Ninety patients with diagnoses of Schatzker V and VI tibial plateau fractures from January 2018 to February 2020 were recruited. The inclusion criteria were as follows: (1) patients more than 18 years of age; (2) patients showing the presence of a unilateral closed tibial plateau fracture with an image inspection that conformed to Schatzker classification standards; (3) patients showing no
coagulopathy or abnormal hemoglobin before operation; and (4) fresh fracture, with a period between injury to hospital admission of less than 3 days. The exclusion criteria were as follows: (1) patients with severe brain, heart, liver, and kidney dysfunction, who could not tolerate surgery; (2) patients with coagulation dysfunction; (3) patients with pathological fractures or tumors; (4) patients with bilateral tibial plateau fractures or other injuries; (5) patients in whom TXA or anticoagulant drugs were contraindicated; (6) patients with incomplete data; (7) preoperative ultrasonography that shows DVT; and (8) the use of spanning external fixation as a primary treatment upon patient admission. In addition, if the surgeon chose to fill the collapsed articular surface with an autologous bone graft during surgery, that patient's data were excluded from statistical analysis, as it was considered that the extra wound incision and blood loss from the iliac bone may have affected the results.

**Intervention**

Patients were divided into the control group, i.v. group, and topical group based on a computer-generated randomization schedule. The control group received an equal amount of placebo (physiological saline solution) as i.v. (total 200 mL) and topical (75 mL) treatments. The i.v. group received 1.0 g i.v. TXA before the tourniquet was inflated and before the surgical incision was closed. Five minutes prior to the final tourniquet release, the topical group received 3.0 g TXA in 75 mL of physiological saline solution, which was injected retrogradely into the joint cavity through a drainage tube placed deep in the incision. The drainage tube was temporarily clamped for 4 hours after the operation. In the control group, an equal volume of saline was used. The therapeutic doses of these regimens were determined from previous studies\textsuperscript{17-20}.

**Surgical Methods and Postoperative Management**

All other drugs, except for TXA and physiological saline solution during general anesthesia, were the same in all three groups. The pressure of the balloon-type tourniquet on the affected limb was set to 450 mmHg, and the mean arterial blood pressure (MAP) was maintained at 60–70 mmHg. Surgical procedure as described previously\textsuperscript{5,21}. Briefly, a medial and lateral double incision approach combined with double locking steel plates was used to fix the fracture block. Primarily, a medial incision (posterior medial approach) was performed to expose the fractured end of the medial side. Kirschner wire was used for temporary reduction and this area was fixed with the anatomical locking plate of the proximal tibia. Then, the joint was opened using a lateral incision (anterolateral approach) to fully expose the lateral condyle; the lateral dissection plate of the proximal tibia was used for fixation and artificial bone grafts were used. Before the incision was closed, two drainage tubes were placed in deep part, where the incision was sutured layer by layer. After compressing the sutured incision with a self-adhesive elastic bandage, the tourniquet was loosened. The drainage pipes for each patient were temporarily clamped for 4 hours after the operation. After the operation, the leg was raised for 3 to 4 days, and the drainage tubes were removed within 48 hours. Functional exercises related to the active and passive ranges of motion were started approximately 2 weeks after surgery. The RBC transfusion indications formulated by the Chinese
Ministry of Health are as follows: 1) Hb < 70 g/L, and 2) 70 g/L < Hb < 100 g/L, when the patient has symptoms of dizziness, palpitation, asthma, and fatigue.

**Study Objectives**

The following demographic data were recorded for each patient: sex, age, body mass index (BMI), medical history, American Society of Anesthesiologists score\(^{22}\) (ASA), fracture type, and preoperative levels of hemoglobin (Hb), hematocrit (Hct), D-dimer, and fibrinogen (FIB). The operation time and intraoperative blood loss were also included in the statistics. Furthermore, laboratory data (e.g., Hb, Hct, D-dimer, and FIB) were also evaluated 24 h after surgery and on the third postoperative day (POD 3). To evaluate the safety of TXA in this study, any vascular event that occurred within 12 weeks after surgery was assessed, including DVT of the lower extremity (confirmed using ultrasound), pulmonary embolism (PE, confirmed using pulmonary spiral CT), cerebrovascular accidents (confirmed using spiral CT or MRI), gastrointestinal hemorrhage, as well as the incidence of wound complications (e.g., dehiscence, hematoma, edge necrosis, and infection). Potential adverse side effects of TXA, including epilepsy, rash, headache, nausea, and vomiting, were also monitored. The Hospital for Special Surgery (HSS) knee score, a 12-item short form health survey (SF-12) and visual analog scale (VAS) were used to evaluate patient outcomes. Owing to the granularity of the SF-12 scoring system, we divided it into two parts, namely, the physical component summary (PCS) and mental component summary (MCS), for comparison\(^{23}\).

**Calculation of perioperative blood loss**

Perioperative total blood loss (TBL) and hidden blood loss (HBL) were the focal points of this study. Intraoperative blood loss (IBL) was estimated from the weight of the surgical sponges and the measurement of the volume of blood collected by the suction canisters. The weight of the irrigation fluids added to the surgical field and the sponge weight were then subtracted from this value. The total postoperative drainage (TPD) was the weight of fluid in the drainage bag collected over 48 hours.

Primarily, the preoperative blood volume (PBV) was calculated using Nadler’s equation\(^{24}\): \(PBV \ (L) = K_1 \times h^3 + K_2 \times w + K_3\), \([h: \text{height (m), } w: \text{weight (kg)}]\); for male patients, \(K_1 = 0.3669\), \(K_2 = 0.03219\), and \(K_3 = 0.6041\); for female patients, \(K_1 = 0.3561\), \(K_2 = 0.03308\), and \(K_3 = 0.1833\). The total blood loss (TBL) was calculated according to the Gross formula\(^{25}\): \(TBL \ (mL) = PBV \times (Hct_1 - Hct_2) \times Hb_{\text{trans}}\), where \(Hct_1\) is the first routine blood test after the patient was admitted to the hospital, \(Hct_2\) is the lowest value obtained by routine blood tests after surgery (24 hours or POD3), and \(Hb_{\text{trans}}\) is the weight of the transfused packed red blood cells (PRBCs), where two units of PRBCs can cause an Hb increase of approximately 5.2 g/dL, with a volume of approximately 400 mL\(^{26}\). All transfused blood products were fresh and stored frozen.

Lastly, hidden blood loss (HBL) was calculated as follows:

\[HBL \ (mL) = TBL - IBL - TPD.\]

**Statistical Analysis**
Statistical analyses were performed using GraphPad Prism 8.0. Continuous variables were reported as the mean and standard deviation. One-way analysis of variance (ANOVA) was used to compare the differences among multiple groups. Student’s t-test was used to compare the difference between two groups and the Chi-square test was used for the analysis of categorical data. P values < 0.05 were considered to indicate a statistically significant difference.

Results

Patient Demographics

All 90 patients included in the study were followed up postoperatively for 12 weeks, so no patients were lost to follow-up. There were no significant differences in the demographic data and preoperative blood test results among the three groups of patients (Table 1).

Table 1. Patient demographic data and preoperative blood test results
| Variable                     | Control group (30 patients) | i.v. group (30 patients) | Topical group (30 patients) | P value (between groups) |
|------------------------------|-----------------------------|--------------------------|----------------------------|--------------------------|
| Patient characteristics      |                             |                          |                            |                          |
| Age (yr)                     | 44.6±6.7                    | 43.8±5.5                 | 45.1±6.3                   | 0.715<sup>a</sup>         |
| Gender (male/female)         | 24/6                        | 25/5                     | 28/2                       | 0.311<sup>b</sup>         |
| BMI                          | 23.1±1.4                    | 22.9±1.5                 | 23.2±1.7                   | 0.745<sup>a</sup>         |
| Medical history              |                             |                          |                            |                          |
| Diabetes mellitus            | 1                           | 1                        | 1                          | 1.000<sup>b</sup>         |
| Hypertension                 | 3                           | 1                        | 2                          | 0.585<sup>b</sup>         |
| Arrhythmia                   | 1                           | 2                        | 2                          | 0.809<sup>b</sup>         |
| ASA score                    |                             |                          |                            |                          |
| Ⅰ                           | 24                          | 24                       | 23                         | 0.966<sup>b</sup>         |
| Ⅱ                           | 4                           | 5                        | 5                          |                          |
| Ⅲ                           | 2                           | 1                        | 2                          |                          |
| Schatzker type               |                             |                          |                            |                          |
| Ⅰ                           | 14                          | 17                       | 11                         | 0.300<sup>b</sup>         |
| Ⅱ                           | 16                          | 13                       | 19                         |                          |
| Preoperative blood tests     |                             |                          |                            |                          |
| Hb (g/dL)                    | 12.7±1.0                    | 12.8±0.9                 | 13.1±1.4                   | 0.360<sup>a</sup>         |
| Hct (%)                      | 39.2±2.7                    | 39.1±2.1                 | 40.1±3.1                   | 0.283<sup>a</sup>         |
| D-dimer (mg/L)               | 6.3±1.2                     | 6.7±1.7                  | 6.1±0.8                    | 0.191<sup>a</sup>         |
| FIB (g/L)                    | 4.6±1.1                     | 5.2±1.5                  | 4.8±1.2                    | 0.172<sup>a</sup>         |

Abbreviations: BMI, Body mass index; ASA, American Society of Anesthesiologists; Hb, Hemoglobin; Hct, Hematocrit; FIB, fibrinogen.

Intergroup comparisons performed using ANOVA or Chi-square test (<sup>a</sup>ANOVA; <sup>b</sup>Chi-square test).

**Operation Time, IBL, and TPD**

The mean operation time in the control, i.v., and topical groups was 117.7±19.4, 109.1±17.5, and 115.3±20.5 min, respectively. There was no significant difference between these values (P = 0.206), although the time in the i.v. group was shorter than in the other groups. The average values of IBL in the control, i.v., and topical groups were 144.5±21.1, 116.5±15.2, and 137.5±19.2 mL, respectively, which were significantly different (P < 0.001); the best effect occurred in the i.v. group (P < 0.001). The topical group
showed the greatest reduction in TPD among the three groups, with a significant difference compared to the i.v. group (64.1 mL vs 76.5 mL, P = 0.004) (Table 2).

Table 2. Postoperative data and postoperative blood test results

| Variable               | Control group (30 patients) | i.v. group (30 patients) | Topical group (30 patients) | P value (between groups) | Intergroup comparison |
|------------------------|-----------------------------|--------------------------|-----------------------------|--------------------------|------------------------|
|                        |                             |                          |                             |                          | $P_1$ | $P_2$ | $P_3$ |
| **Surgical data**      |                             |                          |                             |                          |                  |                  |
| Duration of surgery (min) | 117.7±19.4                 | 109.1±17.5               | 115.3±20.5                  | 0.206$^a$                | -     | -     | -     |
| Duration of tourniquet (min) | 97.3±8.5                   | 95.4±10.1                | 101.6±11.4                  | 0.056$^a$                | -     | -     | -     |
| IBL (mL)               | 144.5±21.1                  | 116.5±15.2               | 137.5±19.2                  | < 0.001$^a$              | < 0.001 | 0.184 | < 0.001 |
| TPD (mL)               | 156.3±27.6                  | 76.5±15.2                | 64.1±16.3                   | < 0.001$^a$              | < 0.001 | < 0.001 | 0.004 |
| **Postoperative blood tests** |                        |                          |                             |                          |                  |                  |
| HB (g/dL)              |                             |                          |                             |                          |                  |                  |
| 24 h                   | 11.7±1.1                    | 12.2±2.2                 | 11.9±0.8                    | 0.430$^a$                | -     | -     | -     |
| POD#3                  | 11.2±2.4                    | 12.5±3.4                 | 11.6±1.2                    | 0.125$^a$                | -     | -     | -     |
| Hct (%)                |                             |                          |                             |                          |                  |                  |
| 24 h                   | 33.5±4.1                    | 34.1±3.9                 | 33.7±4.4                    | 0.849$^a$                | -     | -     | -     |
| POD#3                  | 33.7±2.9                    | 34.6±2.4                 | 34.1±3.1                    | 0.466$^a$                | -     | -     | -     |
| D-dimer (mg/L)         |                             |                          |                             |                          |                  |                  |
| 24 h                   | 9.6±3.4                     | 8.1±2.9                  | 8.4±3.3                     | 0.165$^a$                | -     | -     | -     |
| POD#3                  | 11.2±4.1                    | 9.8±3.1                  | 10.3±3.8                    | 0.335$^a$                | -     | -     | -     |
| FIB (g/L)              |                             |                          |                             |                          |                  |                  |
| 24 h                   | 5.7±2.1                     | 5.1±1.9                  | 5.4±2.3                     | 0.546$^a$                | -     | -     | -     |
| POD#3                  | 7.4±2.6                     | 6.4±1.3                  | 6.8±2.9                     | 0.264                    | -     | -     | -     |
| Real Hb decrease (g/dL)| 1.5±0.6                     | 0.9±0.3                  | 1.2±0.4                     | < 0.001$^a$              | < 0.001 | 0.026 | 0.002 |
| Transfusion rate [%]   | 6.7%                        | 0                       | 0                           | 0.129$^b$                | -     | -     | -     |

Abbreviations: POD#3, the third postoperative day.

$P_1$ represents the P value obtained by comparison between control group and i.v. group;
$P_2$ represents the $P$ value obtained by comparison between control group and topical group;

$P_3$ represents the $P$ value obtained by comparison between i.v. group and topical group;

Intergroup comparisons performed using AVONA or Chi-square test ($^a$ANOVA; $^b$Chi-square test).

**Postoperative Blood Tests**

The results of the routine blood tests and blood coagulation tests in the three groups are summarized in Table 2. The mean values of postoperative Hb at 24 hours in the control, i.v., and topical groups were 11.7±1.1, 12.2±2.2, and 11.9±0.8 g/dL, respectively, with no significant difference between the groups ($P$ = 0.430). The mean values of POD3 Hb in the control, i.v., and topical groups were 11.2±2.4, 12.5±3.4, and 11.6±1.2 g/dL respectively, and there was also no significant difference between the groups ($P$ = 0.125). Similarly, there were no significant differences in the mean Hct values between groups for the above two time points. However, there was a statistically significant difference in the average real Hb reduction among the three groups ($P$ < 0.001): the values were 1.5±0.6 g/dL in the control group, 0.9±0.3 g/dL in the i.v. group, and 1.2±0.4 g/dL in the topical group. The best effect was observed for the i.v. group ($P$ = 0.002, versus the topical group).

The mean values of postoperative D-dimer after 24 h in the control, i.v., and topical groups were 9.6±3.4, 8.1±2.9, and 8.4±3.3 mg/L, respectively, with no significant difference between groups ($P$ = 0.165). The mean values of POD3 D-dimer in the control, i.v., and topical groups were 11.2±4.1, 9.8±3.1, 10.3±3.8 mg/L, respectively, with no significant difference between groups ($P$ = 0.335). Similarly, there were no significant differences for mean FIB values among the three groups at the above two time points (all $p$ values >0.05).

**Blood Loss and Transfusion**

After careful calculation and verification, we found that there were significant differences in TBL among the three groups ($P$ < 0.001). The pairwise comparisons and statistical analyses between groups, namely, control group vs i.v. group, i.v. group vs topical group, and control group vs topical group, all showed statistically significant differences (Fig. 1). Similar results were also obtained for HBL; the HBL values in the control, i.v., and topical groups were 341.1±43.7, 219.3±33.4, and 224.5±33.6 mL, respectively (all intergroup $P$ values < 0.001) (Fig. 2).

The final analysis revealed that two patients in the control group were transfused with 2 units of PRBCs owing to symptoms of postoperative anemia, whereas no patients in the i.v. group and the topical group required blood transfusion. No statistical differences were found in the transfusion rate among the three groups ($P$ = 0.129) (Table 2).

**Vascular Events, Wound Complications, and Adverse Reactions**
In this study, the venous plexus of the calf muscle was the most common site for DVT, followed by the popliteal vein. No severe complications, such as pulmonary embolism, myocardial infarction, or cerebral infarction, occurred to any patient enrolled in this study. There were no significant differences in wound complications and adverse reactions among the three groups. The specific data are described in Table 3.

Table 3. Vascular events, wound complications, and adverse reactions resulting from TXA

| Variable          | Control group (30 patients) | i.v. group (30 patients) | Topical group (30 patients) | P value (between groups) |
|-------------------|-----------------------------|--------------------------|----------------------------|--------------------------|
| **Vascular events**                                    |                            |                          |                            |                          |
| DVT               | 3                           | 5                        | 3                          | 0.661                    |
| MI                | 0                           | 0                        | 0                          | -                        |
| CI                | 0                           | 0                        | 0                          | -                        |
| PE                | 0                           | 0                        | 0                          | -                        |
| GIH               | 0                           | 1                        | 0                          | 0.364                    |
| Total             | 3                           | 6                        | 3                          | 0.421                    |
| **Wound complications**                                |                            |                          |                            |                          |
| Dehiscence        | 0                           | 0                        | 0                          | -                        |
| Hematoma          | 0                           | 0                        | 0                          | -                        |
| Edge necrosis     | 0                           | 0                        | 0                          | -                        |
| Infection         | 1                           | 0                        | 0                          | 0.364                    |
| Total             | 1                           | 0                        | 0                          | 0.364                    |
| **Adverse reactions**                                  |                            |                          |                            |                          |
| Epilepsy          | 0                           | 0                        | 0                          | -                        |
| Rash              | 0                           | 1                        | 0                          | 0.364                    |
| Headache          | 2                           | 4                        | 1                          | 0.338                    |
| Nausea and Vomiting | 1                       | 1                        | 1                          | 1.000                    |
| Total             | 3                           | 6                        | 2                          | 0.260                    |

Abbreviations: TXA, tranexamic acid; DVT, deep vein thrombosis; MI, myocardial infarction; CI, cerebral infarction; PE, pulmonary embolism; GIH, gastrointestinal hemorrhage.

Chi-square test was performed for intra-group comparisons

**Pain, Functional, and QoL assessment (Figures. 3,4,5)**

According to our results, topical TXA had the best effect on pain control in the early postoperative period (POD2 and POD4, P = 0.002 and 0.025, respectively), as well as in the later periods (PO6W, P <0.001).
The knee function HSS scores were used to assess the knee function in patients both before and after surgery. Although there were no significant differences in postoperative follow-up among the three groups at PO 6W and PO 12W (P values: 0.052 and 0.432), it is worth mentioning that the topical group benefitted the most, followed by the i.v. group.

To assess the overall knee function, we used both the PCS and MCS of the SF-12. In PCS, the topical group showed a sustainable development advantage from the 6th week to the 12th week after surgery (P = 0.237 and 0.051, respectively). This advantage is likely to become more significant as the follow-up time increases. The same conclusion also applies to the comparison of MCS among the three groups.

**Discussion**

Our research focus has always been on blood loss reduction during orthopedic surgery. Patients who have not developed anemia and have higher hemoglobin levels show better performance during rehabilitation training and may have additional benefits such as a better QoL. An effective blood preservation strategy is the key to ERAS after orthopedic surgery. TXA, an important component of blood management during orthopedic surgery, makes this strategy a reality.

In this study, the use of TXA reduced IBL and TPD. Compared to the control group, the i.v. regimen effectively reduced blood loss by approximately 28 mL (P < 0.001). The topical regimen can also significantly reduce TPD by approximately 92 mL compared to that in the control group (P < 0.001); this conclusion was also reached by Artit et al. The i.v. regimen reduced real Hb reduction more effectively during the perioperative period, similar to the results of a study conducted by Tzatzairis et al.

Sehat et al. first proposed the concept of HBL and studied the HBL of 63 patients who underwent TKA. They found that HBL accounted for approximately 50% of the TBL. Guo et al. found that the TBL of perioperative patients during hip replacement was approximately 859 mL and the HBL was approximately 525 mL, which accounted for 61% of the TBL. Foss et al. studied the hidden blood loss after hip fracture and found that different surgical schemes caused a hidden blood loss of 500–1473 mL, which was approximately 2 to 3 times greater than the visible blood loss. Therefore, to reduce blood loss in orthopedic surgery, HBL reduction should be the priority. The main finding of our study was that both intravenous and topical TXA can effectively reduce TBL during the perioperative period, and that the intravenous regimen had the strongest effect (approximately 87 mL compared to the topical group, P < 0.001). Similarly, the perioperative HBL was also reduced; however, there was no significant difference between the i.v. regimen and topical regimen.

It has been proposed that the use of tourniquets will lead to excessive fibrinolysis and blood loss within the first 6 hours after surgery. In the current study, the second TXA application in the i.v. group was before the tourniquet release; thus, its effect may have been weakened since the fibrinolytic response was already in progress. The topical application of TXA allows it to rapidly reach the active bleeding point and directly interact with the wound, inhibiting the fibrinolytic reaction in the blood, promoting the formation
of fibrin and maintaining a stable clot, reducing the leakage of blood to the surface of the damaged tissue, and exerting hemostatic effects\textsuperscript{37}. Thus, this explains why there were no significant differences between the i.v. group and topical groups in IBL and TPD.

Thus far, most orthopedic clinical trials have been designed to test the hemostatic effect of TXA instead of its safety. In rare complications, such as pulmonary embolism, the current clinical trial sample size cannot reach a definitive conclusion. The results of this study showed that patients were safe whether they received i.v. or topical treatment. The i.v. regimen appeared to increase the incidence of vascular events and adverse reactions, but with fewer wound complications compared to the control group; however, this difference was not significant. Some studies have confirmed that plasmin not only promotes the activation of monocytes, platelets, and endothelial cells but also plays an important role in stimulating the release of inflammatory mediators and the induction of related pro-inflammatory gene expression. TXA is an inhibitor of plasmin; thus, ammonia TXA also has potential anti-inflammatory effects\textsuperscript{38,39}. In addition, reducing the perioperative blood transfusion rate may also reduce the incidence of wound complications\textsuperscript{40}. The potential mechanism and advantage of the topical administration of TXA is to directly target the site of bleeding just before wound closure. The inhibition of local fibrinolytic activity helps prevent fibrin clot dissolution and increases its volume and strength at the raw surgical surfaces, enhancing microvascular hemostasis\textsuperscript{41}. In addition, TXA has lower systemic absorption. At present, topical articular cavity administration has become one of the best alternatives compared with i.v.\textsuperscript{15,16,18-20,41}. The results of our study also confirmed this result, since the topical group had a lower incidence of vascular events and wound complications, and also provided the benefit of reducing blood loss. Hence, we believe that the use of topical TXA in this study has been shown to be safe. The Chinese guidelines for the prevention of venous thromboembolism after orthopedic surgery recommend that anticoagulants should be used for at least 10 to 14 days after orthopedic surgery; however, as surgeons, we must weigh the expected benefits and risks, and determine the balance between the coagulation and fibrinolysis systems. In our institution, we used TXA to achieve this balance and have presented our preliminary results in this study\textsuperscript{14,26}.

Another important finding in this study was that pain was significantly reduced in patients in the topical group during the early and late postoperative periods. Patients in the topical group received 75 mL TXA, which was retrogradely perfused into the deep part of the incision through the drainage device. The drainage tube was temporarily clamped for 4 hours and a self-adhesive elastic bandage was used to compress the incision again. We believe that the intra-articular pressure in patients in the topical group was higher than that in the control and i.v. groups, which helped reduce pain caused by hematoma stimulation and swelling\textsuperscript{42}. In addition, the HSS of patients in the topical group had a slight advantage in postoperative knee function. This advantage is reflected in the fact that patients can perform a wider range of knee mobility exercises and early ambulation. This can explain the long-term, higher PCS in the topical group in terms of postoperative QoL; however, this difference was not adequate to show statistical significance.
There are some limitations to our study. First, the sample size of this study was small and the results were obtained from a single center. A large-scale prospective, randomized case-control study is needed to further confirm these results. Second, according to the Chinese guidelines for the prevention of venous thromboembolism after orthopedic surgery, all patients received preventive anticoagulation after admission, which may have affected the rate of blood loss. Third, blood loss in postoperative wound dressings was not measured in this study.

Conclusion

In summary, for complex Schatzker type 5 and 6 tibial plateau fractures, the use of TXA is reasonable, safe, and effective. The i.v. regimen offers the advantage of lower perioperative blood loss, whereas the topical regimen can reduce the incidence of vascular events, wound complications, adverse reactions, as well as reduce postoperative pain.

Abbreviations

TXA, tranexamic acid; i.v., intravenous; QoL, quality of life; TBL, total blood loss; HBL, hidden blood loss; RBC, red blood cell; DVT, deep vein thrombosis; MAP, mean arterial blood pressure; ASA, American Society of Anesthesiologists score; Hb, hemoglobin; Hct, hematocrit; FIB, fibrinogen; BMI, body mass index; HSS, Hospital for special surgery; SF-12, the 12-item Short Form Health Survey; VAS, visual analog scale; PE, pulmonary embolism; IBL, intraoperative blood loss; TPD, total postoperative drainage; PBV, preoperative blood volume; PCS, physical component summary; MCS, mental component summary.

Declarations

Ethics approval and consent to participate

Approval was obtained from the Clinical Trials and Biomedical Ethics Committee of Hong Hui Hospital (Approval Number: 2018002), and written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Availability of data and material

All data generated or analyzed during this study are included in this published article.

Declaration of conflict of interest

The authors declare no conflict of interest.

Funding
This study was supported by Project of Science and Technology Department of Shaanxi Province (No. 2016SF-340, No. 2017ZDXM-SF-009 and No. 2019JQ-976).

Authors’ contributions

BZ and KZ were responsible for the study design, the definition of intellectual content, and for literature research. ZMWYL and CR analyzed and interpreted data. LLS and TM performed the statistical analysis. ZMWYL and QW drafted the manuscript. TM, CR ZL and JRY revised the manuscript. All authors read and approved the final manuscript.

Acknowledgement

This work was supported by the Project of Science and Technology Department of Shaanxi Province (2016SF-340; 2017ZDXM-SF-009; 2019JQ-976).

References

1. Parratte S, Ollivier M, Argenson JN. Primary total knee arthroplasty for acute fracture around the knee. Orthop Traumatol Surg Res. 2018;104(1s):S71-s80.
2. Stevenson I, McMillan TE, Baliga S, Schemitsch EH. Primary and Secondary Total Knee Arthroplasty for Tibial Plateau Fractures. J Am Acad Orthop Surg. 2018;26(11):386-395.
3. Kalmet PHS, Van Horn YY, Sanduleanu S, Seelen HAM, Brink PRG, Poeze M. Patient-reported quality of life and pain after permissive weight bearing in surgically treated trauma patients with tibial plateau fractures: a retrospective cohort study. Arch Orthop Trauma Surg. 2019;139(4):483-488.
4. Shen QJ, Zhang JL, Xing GS, Liu ZY, Li EQ, Zhao BC, Zheng YC, Cao Q, Zhang T. Surgical Treatment of Lateral Tibial Plateau Fractures Involving the Posterolateral Column. Orthop Surg. 2019;11(6):1029-1038.
5. Song Z, Wang Q, Ma T, Wang C, Yang N, Xue H, Li Z, Zhu Y, Zhang K. Failure analysis of primary surgery and therapeutic strategy of revision surgery for complex tibial plateau fractures. J Orthop Surg Res. 2019;14(1):110.
6. Schnettler T, Papillon N, Rees H. Use of a Tourniquet in Total Knee Arthroplasty Causes a Paradoxical Increase in Total Blood Loss. J Bone Joint Surg Am. 2017;99(16):1331-1336.
7. Dao P, Massin P. Blood management in enhanced recovery after hip and knee replacement. Orthop Traumatol Surg Res. 2020;106(1s):S1-s5.
8. Wang HY, Wang L, Luo ZY, Wang D, Tang X, Zhou ZK, Pei FX. Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial. BMC Musculoskelet Disord. 2019;20(1):478.
9. Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, Bini SA, Clarke HD, Schemitsch E, Johnson RL, Memtsoudis SG, Sayeed SA, Sah AP, Della Valle CJ. The Efficacy of
Tranexamic Acid in Total Knee Arthroplasty: A Network Meta-Analysis. J Arthroplasty. 2018;33(10):3083-3089.e4.

10. Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, Shatzel JJ. The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020;104(2):79-87.

11. Spitler CA, Row ER, Gardner WE 2nd, Swafford RE, Hankins MJ, Nowotarski PJ, Kiner DW. Tranexamic Acid Use in Open Reduction and Internal Fixation of Fractures of the Pelvis, Acetabulum, and Proximal Femur: A Randomized Controlled Trial. J Orthop Trauma. 2019;33(8):371-376.

12. Tian S, Shen Z, Liu Y, Zhang Y, Peng A. The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA. Injury. 2018;49(3):680-684.

13. Xie B, Tian J, Zhou DP. Administration of Tranexamic Acid Reduces Postoperative Blood Loss in Calcaneal Fractures: A Randomized Controlled Trial. J Foot Ankle Surg. 2015;54(6):1106-1110.

14. Lei J, Zhang B, Cong Y, Zhuang Y, Wei X, Fu Y, Wei W, Wang P, Wen S, Huang H, Wang H, Han S, Liu S, Zhang K. Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial. J Orthop Surg Res. 2017;12(1):124.

15. Bradley KE, Ryan SP, Penrose CT, Grant SA, Wellman SS, Attarian DE, Green CL, Risoli T Jr, Bolognesi MP. Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial. Bone Joint J. 2019;101-b(9):1093-1099.

16. Zhou XD, Zhang Y, Jiang LF, Zhang JJ, Zhou D, Wu LD, Huang Y, Xu NW. Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single-Blind Randomized Controlled Trial. Orthop Surg. 2019;11(4):635-642.

17. Xu S, Chen JY, Zheng Q, Lo NN, Chia SL, Tay KJD, Pang HN, Shi L, Chan ESY, Yeo SJ. The safest and most efficacious route of tranexamic acid administration in total joint arthroplasty: A systematic review and network meta-analysis. Thromb Res. 2019;176:61-66.

18. Jules-Elysee KM, Tseng A, Sculco TP, Baaklini LR, McLawhorn AS, Pickard AJ, Qin W, Cross JR, Su EP, Fields KG, Mayman DJ. Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels. J Bone Joint Surg Am. 2019;101(23):2120-2128.

19. King L, Randle R, Dare W, Bernaitis N. Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial. Orthop Traumatol Surg Res. 2019;105(6):1073-1077.

20. Alshryda S, Sukeik M, Sarda P, Blenkinsopp J, Haddad FS, Mason JM. A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J. 2014;96-b(8):1005-1015.

21. Wu WY, Xu WG, Wan CY, Fang M. Preoperative Plan with 3D Printing in Internal and External Fixation for Complex Tibial Plateau Fractures. Orthop Surg. 2019;11(4):560-568.
22. Bronheim RS, Caridi JM, Steinberger J, Hunter S, Neifert SN, Deutsch BC, DeMaria S Jr, Hermann L, Gal JS. American Society of Anesthesiologists' Status Association With Cost and Length of Stay in Lumbar Laminectomy and Fusion: Results From an Institutional Database. Spine. 2020;45(5):333-338.

23. Roelen CA, Heymans MW, Thun E, Reknes I, Laaksonen M, Magerøy N, Twisk J, Bjorvatn B, Pallesen S, Moen BE. Predictive Value of the SF-12 for Sickness Absence Because of Mental, Musculoskeletal, and Other Somatic Disorders. J Occup Environ Med. 2015;57(10):1113-1118.

24. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224-232.

25. Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983;58(3):277-280.

26. Wang W, Duan K, Ma M, Jiang Y, Liu T, Liu J, Hao D. Tranexamic Acid Decreases Visible and Hidden Blood Loss Without Affecting Prethrombotic State Molecular Markers in Transforaminal Thoracic Interbody Fusion for Treatment of Thoracolumbar Fracture-Dislocation. Spine. 2018;43(13):E734-e739.

27. Ramkumar DB, Ramkumar N, Tapp SJ, Moschetti WE. Pharmacologic Hemostatic Agents in Total Joint Arthroplasty-A Cost-Effectiveness Analysis. J Arthroplasty. 2018;33(7):2092-2099.e2099.

28. Zhao H, Xiang M, Xia Y, Shi X, Pei FX, Kang P. Efficacy of oral tranexamic acid on blood loss in primary total hip arthroplasty using a direct anterior approach: a prospective randomized controlled trial. Int Orthop. 2018;42(11):2535-2542.

29. Zhang S, Huang Q, Xu B, Ma J, Cao G, Pei F. Effectiveness and safety of an optimized blood management program in total hip and knee arthroplasty: A large, single-center, retrospective study. Medicine. 2018;97(1):e9429.

30. Roberts I. Tranexamic acid in trauma: how should we use it? J Thromb Haemost. 2015;13 Suppl 1:S195-199.

31. Laoruengthana A, Rattanaprichavej P, Rasamimongkol S, Galassi M, Weerakul S, Pongpirul K. Intra-Articular Tranexamic Acid Mitigates Blood Loss and Morphine Use After Total Knee Arthroplasty. A Randomized Controlled Trial. J Arthroplasty. 2019;34(5):877-881.

32. Tzatzairis T, Drosos GI, Vogiatzaki T, Tilkeridis K, Ververidis A, Kazakos K. Multiple intravenous tranexamic acid doses in total knee arthroplasty without tourniquet: a randomized controlled study. Arch Orthop Trauma Surg. 2019;139(6):859-868.

33. Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty?. Correct blood loss management should take hidden loss into account. Knee. 2000;7(3):151-155.

34. Guo WJ, Wang JQ, Zhang WJ, Wang WK, Xu D, Luo P. Hidden blood loss and its risk factors after hip hemiarthroplasty for displaced femoral neck fractures: a cross-sectional study. Clin Interv Aging. 2018;13:1639-1645.

35. Foss NB, Kehlet H. Hidden blood loss after surgery for hip fracture. J Bone Joint Surg Br. 2006;88(8):1053-1059.
36. Reikerås O, Clementsen T. Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. J Thromb Thrombolysis. 2009;28(4):425-428.

37. Wang CG, Sun ZH, Liu J, Cao JG, Li ZJ. Safety and efficacy of intra-articular tranexamic acid injection without drainage on blood loss in total knee arthroplasty: A randomized clinical trial. Int J Surg. 2015;20:1-7.

38. Kamio N, Hashizume H, Nakao S, Matsushima K, Sugiya H. Plasmin is involved in inflammation via protease-activated receptor-1 activation in human dental pulp. Biochem Pharmacol. 2008;75(10):1974-1980.

39. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost. 2007;5 Suppl 1:132-142.

40. Carroll K, Dowsey M, Choong P, Peel T. Risk factors for superficial wound complications in hip and knee arthroplasty. Clin Microbiol Infect. 2014;20(2):130-135.

41. Zeng Y, Si HB, Shen B, Yang J, Zhou ZK, Kang PD, Pei FX. Intravenous Combined with Topical Administration of Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Controlled Trial. Orthop Surg. 2017;9(2):174-179.

42. Montroy J, Hutton B, Moodley P, Fergusson NA, Cheng W, Tinmouth A, Lavallée LT, Fergusson DA, Breau RH. The efficacy and safety of topical tranexamic acid: A systematic review and meta-analysis. Transfus Med Rev. 2018 Feb 19:S0887-7963(17)30151-7.

Figures
Figure 1

Comparison of TBL in the three groups. P1 represents the p value obtained by comparison between control group and IV group; P2 represents the p value obtained by comparison between control group and topical group; P3 represents the p value obtained by comparison between IV group and topical group; Intergroup comparisons performed using AVONA test. P1, P2 and P3 < 0.001.
Figure 2

Comparison of HBL in the three groups. P1 represents the p value obtained by comparison between control group and IV group; P2 represents the p value obtained by comparison between control group and topical group; P3 represents the p value obtained by comparison between IV group and topical group; Intergroup comparisons performed using AVONA test. P1 and P2<0.001.
Figure 3

Comparison of VAS pain in the three groups. P1 represents the p value obtained by comparison between control group and IV group; P2 represents the p value obtained by comparison between control group and topical group; P3 represents the p value obtained by comparison between IV group and topical group; 2nd Day post-op: P1 $\leq$ 0.05; P2 $\leq$ 0.001. 4th Day post-op: P2 $\leq$ 0.05. 6-week post-op: P1 $\leq$ 0.001; P2 $\leq$ 0.001.
Figure 4

Comparison of functional in the three groups. There is no difference between the groups at the above time points.
Figure 5

Comparison of PCS and MCS in the three groups. There is no difference between the groups at the above time points.